Acquisitions · Biotechnology (cell therapy)
Astellas buys cell therapy company Ocata for about $379 million
- Buyer
- Astellas Pharma (Tokyo)
- Target
- Ocata Therapeutics, Marlborough, Massachusetts
- Value
- About $379M ($8.50 per share)
- Status
- Agreed on November 10, 2015; completed on February 10, 2016.
- Date
- 2015-11-10
Astellas Pharma agreed to buy Ocata Therapeutics, a Marlborough, Massachusetts developer of cell therapies for eye diseases, for $8.50 per share in cash, or about $379 million. The deal was carried out through a tender offer that was extended twice before it closed on February 10, 2016.
Why it matters
The deal gave Astellas a cell therapy research base in the US and programs in ophthalmology, an area it was building up.
Sources
Kakehashi M&A News home
